MASCC vs CISNE for Febrile Neutropenia

1. Start With Stability

MASCC and CISNE are often mentioned together because both appear in low-risk febrile neutropenia workflows. They should not be used as interchangeable labels. The first question is not "which score is higher?" but whether the patient is clinically stable enough for a low-risk pathway at all.

Both tools support risk discussion but do not replace sepsis assessment, local antimicrobial policy, inpatient/outpatient safety review, or clinician judgment.

2. MASCC vs CISNE Table

3. MASCC Risk Index

The MASCC Risk Index was built to identify febrile neutropenia patients at lower risk for serious medical complications. It includes burden of illness, hypotension, chronic obstructive pulmonary disease, solid tumor or no previous fungal infection, dehydration, outpatient status at fever onset, and age.

In practice, MASCC is useful early in the febrile neutropenia encounter because it gives a shared language for "low risk" versus "not low risk." A score at or above the usual low-risk threshold can support outpatient-pathway consideration only after urgent clinical checks are reassuring.

4. CISNE Score

CISNE was developed for a narrower population: clinically stable patients with solid tumors and febrile neutropenia. It includes ECOG performance status, chronic obstructive pulmonary disease, cardiovascular disease, mucositis, monocyte count, and stress-induced hyperglycemia.

That narrower target population is the point. CISNE is most helpful when the patient looks stable and the team is deciding whether outpatient treatment is appropriate. It should not be used to justify outpatient management for a patient with hypotension, altered mental status, hypoxia, organ dysfunction, uncontrolled symptoms, or inability to return quickly for care.

5. Practical Febrile Neutropenia Workflow

1. Act first on acuity: assess airway, breathing, circulation, mental status, lactate where indicated, organ dysfunction, and sepsis criteria. Give empiric antibiotics promptly according to local policy.
2. Confirm neutropenia context: document ANC, expected duration of neutropenia, chemotherapy timing, malignancy type, prophylaxis, central line status, and suspected infection source.
3. Calculate MASCC: use MASCC for broad risk stratification after initial stabilization steps are in motion.
4. Use CISNE for stable solid-tumor patients: open CISNE when outpatient management is being considered in the population it was designed for.
5. Check outpatient feasibility: review oral intake, renal and hepatic function, allergy profile, local resistance patterns, caregiver support, transport, phone access, distance from hospital, and ability to return within hours.
6. Document the decision: record the score, why the patient is or is not outpatient-eligible, the antimicrobial plan, red flags, follow-up timing, and escalation instructions.

Related supportive-care tools include ECOG Performance Status, Khorana VTE risk, and OncoToolkit supportive care calculators.

6. Limitations And Safety Caveats

• Scores do not treat infection: febrile neutropenia remains an oncologic emergency. Risk tools should not delay empiric antimicrobial therapy.
• Population matters: CISNE is not a general febrile neutropenia score for all cancers and all acuity levels.
• Local policy matters: outpatient eligibility depends on institutional antimicrobial protocols, resistance patterns, observation capacity, and follow-up systems.
• Expected neutropenia duration matters: prolonged profound neutropenia may warrant admission or specialist input even when an initial score appears reassuring.
• Social reliability matters: a low-risk score is not enough if the patient cannot obtain medication, communicate deterioration, or return urgently.

7. Frequently Asked Questions